Raymond James Financial’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.77M Sell
544,188
-32,162
-6% -$739K ﹤0.01% 2266
2026
Q2
$12.8M Buy
576,350
+124,706
+28% +$2.32M ﹤0.01% 1940
2026
Q1
$8.19M Sell
451,644
-78,694
-15% -$1.36M ﹤0.01% 2183
2025
Q4
$10.4M Buy
530,338
+453,426
+590% +$8.59M ﹤0.01% 1933
2025
Q3
$973K Buy
76,912
+25,432
+49% +$290K ﹤0.01% 3689
2025
Q2
$490K Sell
51,480
-1,613
-3% -$17.8K ﹤0.01% 4018
2025
Q1
$555K Sell
53,093
-46,235
-47% -$661K ﹤0.01% 3879
2024
Q4
$2.34M Buy
+99,328
New +$2.94M ﹤0.01% 2851

Other funds holding DYN

Raymond James Financial's DYN Position: Q3 2026 in Review

Raymond James Financial reduced its Dyne Therapeutics (DYN) stake by 5.6% in Q3 2026, selling an estimated $739K and leaving 544,188 shares worth $8.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

Raymond James Financial first reported a position in DYN in Q4 2024 and has held it in 8 quarters since. The position peaked at $12.8M in Q2 2026. 205 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Raymond James Financial held 544,188 shares of Dyne Therapeutics worth $8.77M as of Q3 2026.
  • Raymond James Financial sold 32,162 Dyne Therapeutics shares in Q3 2026, an estimated $739K.
  • Dyne Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #2266 holding.
  • Raymond James Financial first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Dyne Therapeutics position peaked at $12.8M in Q2 2026.
  • 205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.